The quarter cleared the main earnings bar, but not on revenue. Published consensus was roughly $1.20 for non-GAAP EPS and $352.7 million for revenue; HealthEquity delivered $1.24 and $350.7 million, respectively. That makes this an earnings beat driven by profitability, with a modest top-line miss rather than a clean across-the-board upside surprise.
| Metric | Q2 FY27 | Q2 FY26 | Market comparison |
|---|---|---|---|
| Revenue | $350.7M (Financial Highlights) | $325.8M (Financial Highlights) | ~$352.7M consensus |
| Non-GAAP diluted EPS | $1.24 (Non-GAAP reconciliation) | $1.08 (Non-GAAP reconciliation) | ~$1.20 consensus |
| Adjusted EBITDA | $167.0M (Adjusted EBITDA reconciliation) | $151.1M (Adjusted EBITDA reconciliation) | — |
| Adjusted EBITDA margin | 48% (Financial Highlights) | 46% (Financial Highlights) | — |
| FY27 revenue guidance | $1.411B–$1.421B (Outlook) | Prior: $1.410B–$1.420B | — |
| FY27 Adjusted EBITDA guidance | $628M–$636M (Outlook) | Prior: $625M–$633M | — |
Profitability was the genuine upside. Non-GAAP EPS rose 15% year over year to $1.24, while Adjusted EBITDA increased 11% to $167.0 million and margin expanded to 48%. The result suggests cost leverage and execution more than demand acceleration were responsible for the beat.
The underlying franchise remained healthy, but growth was not accelerating everywhere. HSA assets grew 14% to $37.9 billion, HSA accounts increased 8% to 10.7 million, and new HSAs from sales rose 24% to 202,000. However, total CDB accounts declined 2% year over year to 7.0 million, while total revenue grew 8%, below the prior-year quarter's 9% growth rate.
The guidance raise is real but modest, so much of the direction was already known. Management lifted the midpoint of FY27 revenue guidance by only $1 million and the Adjusted EBITDA midpoint by $3 million from the outlook issued after Q1. The better signal is that the company raised targets despite the slight quarterly revenue miss; the limitation is that the revision does not materially reset the year's earnings framework.
Capital returns were aggressive, but cash fell sharply. HealthEquity repurchased $231.1 million of stock in the first half, including $108.1 million in Q2, while ending cash declined to $256.0 million from $318.9 million at January 31. (Cash Flow statement) Debt also remained substantial at $931.1 million. (Condensed consolidated balance sheets) That does not undermine the earnings beat, but it means the stronger per-share result partly benefits from a shrinking share count and comes with less cash on the balance sheet.
Read the original 8-K on SEC EDGAR ↗